White Paper

Companion Diagnostics: Improving Drug Development and Medical Practice

March 13, 2012

Companion diagnostics (CDx), which identifies and detects biomarkers to predict whether a drug works or causes adverse effect in patients, has emerged as an exciting new field. With the cost and hurdles for new drug approval getting increasingly higher, pharmaceutical companies have begun to explore companion tests in order to develop safer, more effective drugs. The value of CDx tests has already been demonstrated by a number of marketed products, such as HercepTest for Herceptin and K-RAS mutation tests for Erbitux and Vectibix.

Download to find out more.